Fuzzy Neural Network Applied to Gene Expression Profiling for Predicting the Prognosis of Diffuse Large B-cell Lymphoma

Overview

Journal Jpn J Cancer Res

Specialty Oncology

Date 2002 Dec 4

PMID 12460461

Citations 13

Authors

Tatsuya Ando

Miyuki Suguro

Taizo Hanai

Takeshi Kobayashi

Hiroyuki Honda

Masao Seto

Affiliations

Soon will be listed here.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the largest category of aggressive lymphomas. Less than 50% of patients can be cured by combination chemotherapy. Microarray technologies have recently shown that the response to chemotherapy reflects the molecular heterogeneity in DLBCL. On the basis of published microarray data, we attempted to develop a long-overdue method for the precise and simple prediction of survival of DLBCL patients. We developed a fuzzy neural network (FNN) model to analyze gene expression profiling data for DLBCL. From data on 5857 genes, this model identified four genes (CD10, AA807551, AA805611 and IRF-4) that could be used to predict prognosis with 93% accuracy. FNNs are powerful tools for extracting significant biological markers affecting prognosis, and are applicable to various kinds of expression profiling data for any malignancy.

Citing Articles

Iterated cross validation method for prediction of survival in diffuse large B-cell lymphoma for small size dataset.

Chang C, Chen C, Hsieh J, Jeng J Sci Rep. 2023; 13(1):1438.

PMID: 36697456 PMC: 9876907. DOI: 10.1038/s41598-023-28394-6.

An intelligent Bayesian hybrid approach to help autism diagnosis.

de Campos Souza P, Guimaraes A, Araujo V, Lughofer E Soft comput. 2021; 25(14):9163-9183.

PMID: 34720705 PMC: 8550741. DOI: 10.1007/s00500-021-05877-0.

Non-Hodgkin Lymphomas: Malignancies Arising from Mature B Cells.

Shingleton J, Wang J, Baloh C, Dave T, Davis N, Happ L Cold Spring Harb Perspect Med. 2020; 11(3).

PMID: 32152246 PMC: 7919396. DOI: 10.1101/cshperspect.a034843.

Ensemble Methods with Voting Protocols Exhibit Superior Performance for Predicting Cancer Clinical Endpoints and Providing More Complete Coverage of Disease-Related Genes.

Jing R, Liang Y, Ran Y, Feng S, Wei Y, He L Int J Genomics. 2018; 2018:8124950.

PMID: 29546047 PMC: 5818887. DOI: 10.1155/2018/8124950.

Improving the Prediction of Survival in Cancer Patients by Using Machine Learning Techniques: Experience of Gene Expression Data: A Narrative Review.

Bashiri A, Ghazisaeedi M, Safdari R, Shahmoradi L, Ehtesham H Iran J Public Health. 2017; 46(2):165-172.

PMID: 28451550 PMC: 5402773.

References

Harada S, Suzuki R, Uehira K, Yatabe Y, Kagami Y, Ogura M . Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia. 1999; 13(9):1441-7. DOI: 10.1038/sj.leu.2401487. View

Uckun F, Sather H, Gaynon P, Arthur D, Nachman J, Sensel M . Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leuk Lymphoma. 1998; 27(5-6):445-57. DOI: 10.3109/10428199709058311. View

Wilson W, Teruya-Feldstein J, Fest T, Harris C, Steinberg S, Jaffe E . Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood. 1997; 89(2):601-9. View

Iida S, Rao P, Butler M, Corradini P, Boccadoro M, Klein B . Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997; 17(2):226-30. DOI: 10.1038/ng1097-226. View

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

Khan J, Wei J, Ringner M, Saal L, Ladanyi M, Westermann F . Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med. 2001; 7(6):673-9. PMC: 1282521. DOI: 10.1038/89044. View

Cerny T, Betticher D . Role of high-dose therapy in diffuse large B-cell lymphoma. Ann Oncol. 2000; 11 Suppl 3:117-21. DOI: 10.1093/annonc/11.suppl_3.117. View

Noguchi H, Hanai T, Honda H, Harrison L, Kobayashi T . Fuzzy neural network-based prediction of the motif for MHC class II binding peptides. J Biosci Bioeng. 2005; 92(3):227-31. DOI: 10.1263/jbb.92.227. View

Pomeroy S, Tamayo P, Gaasenbeek M, Sturla L, Angelo M, McLaughlin M . Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002; 415(6870):436-42. DOI: 10.1038/415436a. View

10.

Shipp M, Richardson N, Sayre P, Brown N, Masteller E, Clayton L . Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proc Natl Acad Sci U S A. 1988; 85(13):4819-23. PMC: 280527. DOI: 10.1073/pnas.85.13.4819. View

11.

Sherlock G, Hernandez-Boussard T, Kasarskis A, Binkley G, Matese J, Dwight S . The Stanford Microarray Database. Nucleic Acids Res. 2000; 29(1):152-5. PMC: 29818. DOI: 10.1093/nar/29.1.152. View

12.

Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T . De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002; 99(3):815-21. DOI: 10.1182/blood.v99.3.815. View

13.

Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K . Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med. 1997; 337(8):529-34. DOI: 10.1056/NEJM199708213370804. View

14.

Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R . High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol. 1998; 16(1):63-9. DOI: 10.1200/JCO.1998.16.1.63. View

15.

. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14):987-94. DOI: 10.1056/NEJM199309303291402. View

16.

Armitage J, Weisenburger D . New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998; 16(8):2780-95. DOI: 10.1200/JCO.1998.16.8.2780. View

17.

Engelhard M, Brittinger G, Huhn D, Gerhartz H, Meusers P, Siegert W . Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood. 1997; 89(7):2291-7. View

18.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

19.

Shipp M, Ross K, Tamayo P, Weng A, Kutok J, Aguiar R . Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002; 8(1):68-74. DOI: 10.1038/nm0102-68. View

20.

Mandel M, Rechavi G, Neumann Y, Biniaminov M, Rosenthal E, Toren A . CD10+ cell population in the bone marrow of patients with advanced neuroblastoma. Med Pediatr Oncol. 1994; 22(2):115-8. DOI: 10.1002/mpo.2950220210. View